A Phase I, Double-blind, Randomized, Placebo Controlled, Dose Escalation Study of Valortim (MDX-1303) Administered Intravenously (IV) as a 120 Minute Infusion in Healthy, Normal Subjects.
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2013
At a glance
- Drugs MDX 1303 (Primary)
- Indications Anthrax
- Focus Adverse reactions
- 01 Aug 2013 Status changed from active, no longer recruiting to completed, according to a PharmAthene media release.
- 13 Apr 2011 PharmAthene completes dosing; the company anticipates safety follow-up to be completed in the third quarter of 2011 with final results available before the end of 2011.
- 13 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to a PharmAthene media release.